Early development of sigma-receptor ligands

Future Medicinal Chemistry

Volumn 3, Issue 1, 2011, Pages 79-94

  Narayanan, Sanju ^a   Bhat, Rohit ^a   Mesangeau, Christophe ^a   Poupaert, Jacques H ^b   McCurdy, Christopher R ^a,c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYL 1 (3 PHENYLPROPYL)PIPERIDINE; ANTINEOPLASTIC AGENT; ANXIOLYTIC AGENT; BUTYROPHENONE DERIVATIVE; CALCIUM ION; CB 184; CB 64D; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLAZOCINE; DEXTROMETHORPHAN; GEMCITABINE; HALOPERIDOL; LEVORPHANOL; LIGAND; MORPHINE; N [2 (3,4 DICHLOROPHENYL)ETHYL] N METHYL 2 (1 PYRROLIDINYL)ETHYLAMINE; N ALLYLNORMETAZOCINE; N CYCLOHEXYL N ETHYL 3 (3 CHLORO 4 CYCLOHEXYLPHENYL) 2 PROPENYLAMINE; NALOXONE; NEUROSTEROID; OCTAHYDROBENZO[F]QUINOLINE; OPIATE AGONIST; PACLITAXEL; PB 28; PHENOTHIAZINE DERIVATIVE; PHENYLALKYLPIPERAZINE; POTASSIUM ION; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; SIRAMESINE; SSR 125329A; SV 119; THIOXANTHENE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WC 26;

CANCER THERAPY; CENTRAL NERVOUS SYSTEM; COCAINE DEPENDENCE; DEPRESSION; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOPLASMIC RETICULUM; HUMAN; ISOTOPE LABELING; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; NEOPLASMS; NERVOUS SYSTEM DISEASES; PROTEIN BINDING; RECEPTORS, SIGMA;

EID: 78650664286     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.279     Document Type: Review

References (121)

1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197, 517-532 (1976).
2. Berzetei-Gurske IP, Toll L. The m-opioid activity of k-opioid receptor agonist compounds in the guinea pig ileum. Eur. J. Pharmacol. 212, 283-286 (1992).
3. Khazan N, Young GA, El-Fakany EE, Hong O, Calligaro D. s receptors mediated the psychotomimetic effects of N-allylnormetazocine (SKF-10,047), but not its opioid agonistic-antagonistic properties. Neuropharmacology 23, 983-987 (1984).
4. Vaupel DB. Naltrexone fails to antagonize the s effects of PCP and SKF 10,047 in the dog. Eur. J. Pharmacol. 92, 269-274 (1983).
5. Iwamoto ET. Locomotor activity and antinociception after putative m, k and s opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists. J. Pharmacol. Exp. Ther. 217, 451-460 (1981).
6. Young GA, Khazan N. Differential neuropharmacological effects of m, k and s opioid agonists on cortical EEG power spectra in the rat. Stereospecificity and naloxone antagonism. Neuropharmacology 23, 1161-1165 (1984).
7. Wong EHF, Knight AR, Woodruff GN. [3H] MK-801 labels a site on the N-methyl-d-aspartate receptor channel complex in rat brain membranes. J. Neurochem. 50, 274-281 (1988).
8. Quirion R, Bowen WD, Itzhak Y et al. A proposal for the classification of s binding sites. Trends Pharmacol. Sci. 13, 85-86 (1992).
9. Aydar E, Palmer CP, Klyachko VA, Jackson MB. The s receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34, 399-410 (2002).
10. Jbilo O, Vidal H, Paul R et al. Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J. Biol. Chem. 272, 27107-27115 (1997).
11. Hanner M, Moebius FF, Flandorfer A et al. Purification, molecular cloning and expression of the mammalian s1-binding site. Proc. Natl. Acad. Sci. USA 93, 8072-8077 (1996).
12. Mei J, Pasternak GW. Molecular cloning and pharmacological characterization of the rat s1 receptor. Biochem. Pharmacol. 62, 349-355 (2001).
13. Pan YX, Mei J, Xu J, Wan BL, Zuckerman A, Pasternak GW. Cloning and characterization of a mouse s1 receptor. J. Neurochem. 70, 2279-2285 (1998).
14. Seth P, Leibach FH, Ganapathy V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 s receptor. Biochem. Biophys. Res. Commun. 241, 535-540 (1997).
15. Seth P, Fei YJ, Li HW, Huang W, Leibach FH, Ganapathy V. Cloning and functional characterization of a s receptor from rat brain. J. Neurochem. 70, 922-931 (1998).
16. Novakova M, Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. Inotropic action of s receptor ligands in isolated cardiac myocytes from adult rats. Eur. J. Pharmacol. 286, 19-30 (1995).
17. Wolfe SA Jr, Ha BK, Whitlock BB, Saini P. Differential localization of three distinct binding sites for s receptor ligands in rat spleen. J. Neuroimmun. 72, 45-58 (1997).
18. Bowen WD. s receptors: recent advances and new clinical potentials. Pharm. Acta Helv. 74, 211-218 (2000).
19. Hayashi T, Su TP. Regulating ankyrin dynamics: roles of s-1 receptors. Proc. Natl. Acad. Sci. USA 98, 491-496 (2001).
20. Hayashi T, Su TP. s-1 receptor chaperones at ER-mitochondria interface regulate calcium signaling and cell survival. Cell 131, 596-610 (2007).
21. Hayashi T, Maurice T, Su TP. Ca2+ signalling via s1-receptors: novel regulatory mechanism affecting intracellular Ca2+ concentration. J. Pharmacol. Exp. Ther. 293, 788-798 (2000).
22. Monnet FP, Debonnel G, Junien JL, De Montigny C. N-Methyl-d -aspartate-induced neuronal activation is selectively modulated by s receptors. Eur. J. Pharmacol. 179, 441-445 (1990).
23. Ablordeppey SY, Fischer JB, Glennon RA. Is a nitrogen atom an important pharmacophoric element in s ligand binding? Bioorg. Med. Chem. 8, 2105-2111 (2000).
24. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. s receptors: biology and function. Pharmacol. Rev. 42, 355-402 (1990).
25. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho, AE. The hallucinogen N,N-Dimethyltryptamine (DMT) is an endogenous s-1 receptor regulator. Science. 323, 934-937 (2009).
26. Roman FJ, Pascaud X, Duffy O, Vauche D, Martin B, Junien JL. Neuropeptide Y and peptide YY interact with brain and PCP binding sites. Eur. J. Pharmacol. 174, 301-302 (1989).
27. Muers A, Clinkers R, Ebinger G, Michotte Y, Smolders I. s-1 receptor-mediated increase in hippocampal extracellular dopamine contributes to the mechanism of the anticonvulsant action of neuropeptide Y. Eur. J. Neurosci. 26, 3079-3092 (2007).
28. Ramachandran S, Chu UB, Mavlyutov TA et al. The s-1 receptor interacts with N-alkyl amines and endogenous sphingolipids. Eur. J. Pharmacol. 609, 19-26 (2009).
29. Hellewell SB, Bowen WD. A s-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different s receptor form from that of guinea pig brain. Brain Res. 527, 244-253 (1990).
30. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of s1 and s2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 268, 9-18 (1994).
31. Bem WT, Thomas GE, Mamone JY et al. Overexpression of s receptors in nonneural human tumors. Cancer Res. 51, 6558-6562 (1991).
32. Vilner BJ, Bowen WD. Characterization of s-like binding sites of NB41A3, S-20Y, and N1E-115 neuroblastomas, C6 glioma, and NG108-15 neuroblastoma-glioma hybrid cells: further evidence for s-2 receptors. In: Mult. Sigma PCP Recept. Ligands: Mech. Neuromodulation Neuroprot., Proc. Jt. Fr.-U.S. Semin, CNRS-NSF, 3rd. Kamenka, Jean-Marc, Domino, Edward F (Eds). 341-353 American chemical society, WA, USA (1992).
33. Mach RH, Smith CR, Al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. s2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res. 57, 156-161 (1997).
34. Chu W, Xu J, Zeng C et al. New N-substituted 9-azabicyclo[3.3.1]nonan-3a- yl phenlcarbamate analogs as s-2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. Bioorg. Med. Chem. 17, 1222-1231 (2009).
35. Vangveravong S, Xu J, Zeng C, Mach RH. Synthesis of N-substituted 9-aza-bucyclo[3.3.1]nonan-3a-yl carbamate analogs as s-2 receptor ligands. Bioorg. Med. Chem. 14, 6988-6997 (2007).
36. Kashiwagi H, McDunn JE, Simon PO. Selective s-2 ligands preferentially bind to pancreatic adenocarcinomas: application in diagnostic imaging and therapy. Mol. Cancer 6, 48 (2007).
37. Kashiwagi H, McDunn JE, Simon PO et al. s-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. J. Transl. Med. 7, 24 (2009).
38. Crawford KW, Bowen WD. s-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 62, 313-322 (2002).
39. Effective tumor cell death by s-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Ostenfeld MS, Fehrenbacher N, Høyer-Hansen M, Thomsen C, Farkas T, Jäättelä M. Cancer Res. 65, 8975-8983 (2005).
40. Crawford KW, Coop A, Bowen WD. s2 receptors regulate changes in sphingolipid levels in breast tumor cells. Eur. J. Pharmacol. 443, 207-209 (2002).
41. Brent PJ, Pang GT. s binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur. J. Pharmacol. 278, 151-160 (1995).
42. Vilner BJ, Bowen WD. s receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur. J. Pharmacol. 244, 199-201 (1993).
43. Azzariti A, Colabufo NA, Berardi F et al. Cyclohexylpiperazine derivative PB28, a s-2 agonist and s-1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein and synergizes with anthracyclines in breast cancer. Mol. Cancer Ther. 5, 1807-1816 (2006).
44. Foster A, Wu H, Chen W et al. 1,4-Dibenzylpiperazines possess anticocaine activity. Bioorg. Med. Chem. Lett. 13, 749-751 (2003).
45. Matsumoto RR, Mack AL. (+)-SM 21 attenuates the convulsive and locomotor stimulatory effects of cocaine in mice. Eur. J. Pharmacol. 417, R1-R2 (2001).
46. Monnet FP, Debonnel G, De Montigny C. In vivo electrophysiological evidence for a selective modulation of N-methyl-d-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by s ligands. J. Pharmacol. Exp. Ther. 261, 123-130 (1992).
47. Morin-Surun MP, Collin T, Denavit-Saubie M, Baulieu EE, Monnet FP. Intracellular s1 receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc. Natl. Acad. Sci. USA 96, 8196-8199 (1999).
48. Campbell BG, Scherz MW, Keana JF, Weber E. s receptors regulate contractions of the guinea pig ileum longitudinal muscle/ myenteric plexus preparation elicited by both electrical stimulation and exogenous serotonin. J. Neurosci. 9, 3380-3391 (1989).
49. Gonzalez-Alvear GM, Werling LL. Regulation of [3H]dopamine release from rat striatal slices by s receptor ligands. J. Pharmacol. Exp. Ther. 271, 212-219 (1994).
50. Weatherspoon JK, Gonzalez-Alvear GM, Frank AR, Werling LL. Regulation of [3H] dopamine release from mesolimbic and mesocortical areas of guinea pig brain by sreceptors. Schizophr. Res. 21, 51-62 (1996).
51. Horan B, Gifford AN, Matsuno K, Mita S, Ashby CR Jr. Effect of SA4503 on the electrically evoked release of 3H-acetylcholine from striatal and hippocampal rat brain slices. Synapse 46, 1-3 (2002).
52. Lobner D, Lipton P. s-ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia. Neurosci. Lett. 117, 169-174 (1990).
53. Su TP. Delineating biochemical and functional properties of s receptors: emerging concepts. Crit. Rev. Neurobiol. 7, 187-203 (1993).
54. Ferris CD, Hirsch DJ, Brooks BP, Snyder SH. s receptors: from molecule to man. J. Neurochem. 57, 729-737 (1991).
55. Roman FJ, Pascaud X, Martin B, Vauche D, Junien JL. JO 1784, a potent and selective ligand for rat and mouse brain s-sites. J. Pharm. Pharmacol. 42, 439-440 (1990).
56. Bermack J, Lavoie N, Dryver E, Debonnel G. Effects of s ligands on NMDA receptor function in the bulbectomy model of depression: a behavioural study in the rat. Int. J. Neuropsychopharmacol. 5, 53-62 (2002).
57. Monnet FP, Debonnel G, Bergeron R, Gronier B, de Montigny C. The effects of s ligands and of neuropeptide Y on N-methyl-d-aspartate-induced neuronal activation of CA3 dorsal hippocampus neurons are differentially affected by pertussis toxin. Br. J. Pharmacol. 112, 709-715 (1994).
58. Guitart X, Codony X, Ballarin M, Dordal A. Farre AJ. E-5842: a new potent and preferential s ligand. Preclinical pharmacological profile. CNS Drug Rev. 4, 201-224 (1998).
59. Okuyama S, Imagawa Y, Ogawa S et al. NE-100, a novel s receptor ligand: in vivo tests. Life Sci. 53, PL285-PL290 (1993).
60. Taylor DP, Dekleva J. BMY 14802: a potential antipsychotic agent that selectively binds to s receptors. In: Sigma Phencyclidine-like Compd. Mol. Probes Biol., [Proc. U.S.-Fr. Sponsored Int. Semin.], 2nd. Domino, Edward F, Kamenka, Jean-Marc (Eds). American chemical society, WA, USA 345-355 (1988).
61. Casellas P, Bourrie B, Canat X et al. Immunopharmacological profile of SR 31747: In vitro and in vivo studies on humoral and cellular responses. J. Neuroimmun. 52, 193-203 (1994).
62. Derocq JM, Bourrie B, Segui M, Le Fur G, Casellas P. In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the s ligand SR 31747. J. Pharmacol. Exp. 272, 224-230 (1995).
63. Bourrie B, Bouaboula M, Menoit JM et al. Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a s ligand. Eur. J. Immun. 25, 2882-2887 (1995).
64. Bourrie B, Benoit JM, Derocq JM et al. A s ligand, SR 31747A, potently modulates Staphylococcal enterotoxin B-induced cytokine production in mice. Immunology 88, 389-393 (1996).
65. Bourrie B, Bribes E, De Nys N et al. SSR125329A, a high affinity s receptor ligand with potent anti-inflammatory properties. Eur. J. Pharmacol. 456, 123-131 (2002).
66. Matsumoto RR, Liu Y, Lerner M, Howard EW, Brackett DJ. s receptors: potential medications development target for anti-cocaine agents. Eur. J. Pharmacol. 469, 1-12 (2003).
67. Takahashi S, Miwa T, Horikomi K. Involvement of s 1 receptors in methamphetamine-induced behavioral sensitization in rats. Neurosci. Lett. 289, 21-24 (2000).
68. de Costa BR, He X. Structure-activity relationships and evolution of sreceptor ligands (1976-present). Sigma Recept. 45-111 (1994).
69. Abou-Gharbia M, Ablordeppey SY, Glennon RA. s receptors and their ligands: the s enigma. Annu. Rep. Med. Chem. 28, 1-10 (1993).
70. Bowen WD, Moses EL, Tolentino PJ, Walker JM. Metabolites of haloperidol display preferential activity at s receptors compared with dopamine D-2 receptors. Eur. J. Pharmacol 177, 111-118 (1990).
71. Maeda DY, Williams W, Kim WE, Thatcher LN, Bowen WD, Coop A. N-arylalkylpiperidines as high-affinity s-1 and s-2 receptor ligands: phenylpropylamines as potential leads for selective s-2 agents. Bioorg. Med. Chem. Lett. 12, 497-500 (2002).
72. Van de Waterbeemd H, El Tayar N, Testa B, Wikstroem H, Largent B. Quantitative structure-activity relationships and eudismic analyses of the presynaptic dopaminergic activity and dopamine D2 and s receptor affinities of 3-(3-hydroxyphenyl)piperidines and octahydrobenzo[f]quinolines. J. Med. Chem. 30, 2175-2181 (1987).
73. Maeda DY, Williams W, Bowen WD, Coop A. A s-1 receptor selective analogue of BD1008. A potential substitute for (+)-opioids in s receptor binding assays. Bioorg. Med. Chem. Lett. 10, 17-18 (2000).
74. Nakazato A, Ohta K, Sekiguchi Y et al. Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine s ligands as potential antipsychotic drugs. J. Med. Chem. 42, 1076-1087 (1999).
75. Largent BL, Wikstroem H, Gundlach AL, Snyder SH. Structural determinants of s receptor affinity. Mol. Pharmacol. 32, 772-784 (1987).
76. Gilligan PJ, Cain GA, Christos TE et al. Novel piperidine s-receptor ligands as potential antipsychotic drugs. J. Med. Chem. 35, 4344-4361 (1992).
77. Glennon RA, Smith JD, Ismaiel AM, el-Ashmawy M, Battaglia G, Fischer JB. Identification and exploitation of the s-opiate pharmacophore. J. Med. Chem. 34, 1094-1098 (1991).
78. Glennon RA, Ismaiel AM, Smith JD et al. Binding of substituted and conformationally restricted derivatives of N-(3-phenyl-N-propyl)-1-phenyl-2- aminopropane at s-receptors. J. Med. Chem. 34, 1855-1859 (1991).
79. Su TP, Wu XZ, Cone EJ et al. s compounds derived from phencyclidine: identification of PRE-084, a new, selective s ligand. J. Pharmacol. Exp. Ther. 259, 543-550 (1991).
80. Matsumoto RR, Bowen WD, Su TP. In: Sigma Receptors: Chemistry, Cell Biology Clinical Implications. (Eds). Springer Science, Business Media, LLC NY, USA 128 (2003).
81. Su TP, London ED, Jaffe JH. Steroid binding at s receptors suggests a link between endocrine, nervous and immune systems. Science 240, 219-221 (1988).
82. Ablordeppey SY, El-Ashmawy M, Fischer JB, Glennon RA. A CoMFA investigation of s receptor binding affinity: reexamination of a spurious s ligand. Eur. J. Med. Chem. 33, 625-633 (1998).
83. Laggner C, Schieferer C, Fiechtner B et al. Discovery of high-affinity ligands of s-1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening. J. Med. Chem. 48, 4754-4764 (2005).
84. Oberdorf C, Schmidt TJ, Wünsch B. 5D-QSAR for spirocyclic s-1 receptor ligands by Quasar receptor surface modeling. Eur. J. Med. Chem. 45, 3116-3124 (2010).
85. Zamoieri D, Mamolo MG, Laurini E et al. Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for s-1 receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives. J. Med. Chem. 52, 5380-5393 (2009).
86. Gund TM, Floyd J, Jung D. Molecular modeling of s-1 receptor ligands: a model of binding conformational and electrostatic considerations. J. Mol. Graph. Model 22, 221-230 (2004).
87. Laurini E, Zampieri D, Mamolo MG et al. A 3D-pharmacophore model for s-2 receptors based on a series of substituted benzo[d] oxazol-2(3H)-one derivatives. Bioorg. Med. Chem. Lett. 20, 2954-2957 (2010).
88. Cratteri P, Romanelli MN, Cruciani G, Bonaccini C, Melani F. GRIND-derived pharmacophore model for a series of a-tropanyl derivative ligands of the s-2 receptor. J. Comp. Aid. Mol. Des. 18, 361-374 (2004).
89. De Costa BR, Bowen WD, Hellewell SB et al. Synthesis and evaluation of optically pure [3H]- (+)-pentazocine, a highly potent and selective radioligand for s receptors. FEBS Lett. 251, 53-58 (1989).
90. Weber E, Sonders M, Quarum M, McLean S, Pou S, Keana JFW. 1,3-Di(2-[5-3H]tolyl) guanidine: a selective ligand that labels s-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. U. S. A. 83, 8784-8788 (1986).
91. Guitart X, Farre AJ. The effect of E-5842, a s receptor ligand and potential atypical antipsychotic, on Fos expression in rat forebrain. Eur. J. Pharmacol. 363, 127-130 (1998).
92. Guitart X, Ballarin M, Codony X et al. E-5842: antipsychotic s-receptor ligand. Drugs Future 24, 386-392 (1999).
93. Huang Y, Hammond PS, Whirrett BR et al. Synthesis and quantitative structure-activity relationships of N-(1-benzylpiperidin-4-yl) phenylacetamides and related analogs as potent and selective s1 receptor ligands. J. Med. Chem. 41, 2361-2370 (1998).
94. Chaki S, Tanaka M, Muramatsu M, Otomo S. NE-100, a novel potent s ligand, preferentially binds to s1 binding sites in guinea pig brain. Eur. J. Pharmacol. 251, R1-R2 (1994).
95. Quaglia W, Giannella M, Piergentili A et al. 1-benzyl-3,4- dihydrospiro[2H-1- benzothiopyran-2,4́-piperidine] (spipethiane), a potent and highly selective s1 ligand. J. Med. Chem. 41, 1557-1560 (1998).
96. Maier CA, Wünsch B. Novel s receptor ligands. Part 2. SAR of Spiro[[2]benzopyran- 1,4́-piperid- ines] and spiro[[2]benzofuran- 1,4́-piperidines] with carbon substituents in position 3. J. Med. Chem. 43, 4923-4930 (2002).
97. Hajipour AR, Fontanilla D, Chu UB, Arbabian M, Ruoho AE. Synthesis and characterization of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for s receptors. Bioorg. Med. Chem. 18, 4397-4404 (2010).
98. Yous S, Wallez V, Belloir M, Caignard DH, McCurdy CR, Poupaert JH. Novel 2(3H)- benzothiazolones as highly potent and selective s-1 receptor ligands. Med. Chem. Res. 14(3), 158-168 (2005).
99. Bowen WD, Bertha CM, Vilner BJ, Rice KC. CB-64D and CB-184: ligands with high s-2 receptor affinity and subtype selectivity. Eur. J. Pharmacol. 278, 257-260 (1995).
100. Vilner BJ, Bowen WD. Modulation of cellular calcium by s-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J. Pharmacol. Exp. Ther. 292, 900-911 (2000).
101. Bowen WD, Vilner BJ, Williams W, Bertha CM, Kuehne ME, Jacobson AE. Ibogaine and its congeners are s2 receptor-selective ligands with moderate affinity. Eur. J. Pharmacol. 279, R1-R3 (1995).
102. Bowen WD. s receptors and iboga alkaloids. Alkaloids Chem. Biol. 56, 173-191 (2001).
103. Moltzen EK, Perregaard J, Meier E. s ligands with subnanomolar affinity and preference for the s2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines. J. Med. Chem. 38, 2009-2017 (1995).
104. Mach RH, Vangveravong S, Huang Y, Yang B, Blair JB, Wu L. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3a-yl phenylcarbamate analogs as s-2 receptor ligands. Med. Chem. Res. 11, 380-398 (2002).
105. Mach RH, Wu L, West T, Whirrett BR, Childers SR. The analgesic tropane analog (±)-SM 21 has a high affinity for s2 receptors. Life Sci. 64, PL131-PL137 (1999).
106. Perregaard J, Moltzen EK, Meier E, Sanchez C. s ligands with subnanomolar affinity and preference for the s2 binding site. 1. 3-(w-aminoalkyl)-1h- indoles. J. Med. Chem. 38, 1998-2008 (1995).
107. Mach RH, Huang Y, Freeman RA, Wu L, Vangveravong S, Luedtke RR. Conformationally-flexible benzamide analogues as dopamine D3 and s2 receptor ligands. Bioorg. Med. Chem. Lett. 14, 195-202 (2004)
108. Berardi F, Ferorelli S, Abate C et al. 4-(tetralin-1-yl)- and 4-(naphthalen-1-yl) alkyl derivatives of 1-cyclohexylpiperazine as s receptor ligands with agonist s2 activity. J. Med. Chem. 47, 2308-2317 (2004).
109. Kawamura K, Ishiwata K, Tajima H et al. In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS s-1 receptors. Nucl. Med. Biol. 27(3), 255-261 (2000).
110. Ishiwata K, Tsukada H, Kawamura K et al. Mapping of CNS s1 receptors in the conscious monkey: preliminary PET study with [11C]SA4503. Synapse 40, 235-237 (2001).
111. Kawamura K, Kimura Y, Tsukada H et al. An increase in s1 receptors in aged monkey brain. Neurobiol. Ageing 24, 745-752 (2003).
112. Ishikawa M, Ishiwata K, Ishii K et al. High occupancy of s-1 receptors in human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503. Biol. Psychiatry. 62(8), 878-883 (2007).
113. Waterhouse RN, Collier TL. In vivo evaluation of [18F]1-(3-fluoropropyl)- 4-(4- cyanophenoxymethyl)piperidine: a selective s-1 receptor radioligand for PET. Nucl. Med. Biol. 24, 127-134 (1997).
114. Waterhouse RN, Stabin MG, Page JG. Preclinical acute toxicity studies and rodent-based dosimetry estimates of the novel s-1 receptor radiotracer [18F]FPS. Nucl. Med. Biol. 30, 555-563 (2003).
115. Kawamura K, Tsukada H, Shiba K et al. Synthesis and evaluation of fluorine-18- labeled SA4503 as a selective s1 receptor ligand for positron emission tomography. Nucl. Med. Biol. 34, 571-577 (2007).
116. Maestrup EG, Fischer S, Wiese C et al. Evaluation of spirocyclic 3-(3-fluoropropyl)- 2-benzofuran as s 1 receptor ligands for neuroimaging with positron imaging tomography. J. Med. Chem. 52, 6062-6072 (2009).
117. Xu J, Ti Z, Jones LA, Vangveravong S, Wheeler KT, Mach RH. [3H]N-[4-(3,4- dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl) butyl]-2-methoxy-5-methylbenzamide: a novel s-2 receptor probe. Eur. J. Pharmacol. 525, 8-17 (2005).
118. Colabufo NA, Abate C, Contino M et al. Tritium radiolabelling of PB28, a potent s2 receptor ligand: pharmacokinetic and pharmacodynamic characterization. Bioorg. Med. Chem. Lett. 18, 2183-2187 (2008).
119. Rowland DJ, Tu Z, Xu J et al. Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled s-2- receptor ligands. J. Nucl. Med. 47(6), 1041-1048 (2006).
120. Tu Z, Jones LA, Li S et al. Fluorine-18-labeled benzamide analogues for imaging the s2 receptor status of solid tumor with positron emission tomography. J. Med. Chem. 50(14), 3194-3204 (2007).
121. Tu Z, Xu J, Jones LA et al.Radiosynthesis and biological evaluation of a promising s2 receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. Appl. Radiat. Isot. 68, 2268-2273 (2010).